Semaglutide Research: Deep Dive Into GLP-1 Receptor Agonist Mechanisms, Clinical Trials, and Beyond Weight Loss

Research Peptides

Shop Our Top Compounds

IPP-3 RT

$89.00

Add to Cart

IPP-2 TRZ

$79.00

Add to Cart

IPP-1 SM 10mg

$60.00

Add to Cart

BPC-157/TB-500 Blend 10mg/10mg (20mg)

$110.00

Add to Cart

BPC-157 10mg

$60.00

Add to Cart

TB-500 10mg

$69.99

Add to Cart

CJC-1295/Ipamorelin Blend 5mg/5mg (No DAC) (10mg)

$60.00

Add to Cart

MOTS-c 10mg

$49.99

Add to Cart

View All Products →

Semaglutide Research: Deep Dive Into GLP-1 Receptor Agonist Mechanisms, Clinical Trials, and Beyond Weight Loss

Semaglutide Research: Deep Dive Into GLP-1 Receptor Agonist Mechanisms, Clinical Trials, and Beyond Weight Loss

All information presented in this article is for research purposes only. Semaglutide and related peptides discussed herein are intended for laboratory and clinical research use. This content does not constitute medical advice, dosage recommendations, or treatment guidance. Not for human consumption outside of supervised clinical research.

Introduction

Few peptide-based compounds have reshaped the landscape of metabolic research as dramatically as semaglutide. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide research has expanded far beyond its initial glycemic control applications into weight management, cardiovascular risk reduction, kidney disease prevention, hepatoprotection, and even neuroprotection and addiction science.

The depth and breadth of semaglutide clinical trials — from the landmark STEP weight management program to the SELECT cardiovascular outcomes trial and the FLOW kidney outcomes study — represent one of the most comprehensive investigational programs for any single peptide compound in modern pharmacology. Published data now span tens of thousands of research subjects across dozens of randomized controlled trials, yielding mechanistic insights that continue to redefine how researchers understand GLP-1 receptor biology.

This article provides an evidence-based review of semaglutide research, examining the molecular design that gives this peptide its unique pharmacokinetic profile, the clinical data from major trial programs, emerging research frontiers beyond metabolic disease, and comparisons with other GLP-1 receptor agonists. For researchers seeking a thorough understanding of the current scientific literature, this deep dive synthesizes findings from peer-reviewed studies published in leading journals including The New England Journal of Medicine, The Lancet, JAMA, and Nature Medicine.

For protocol-specific guidance for research applications, see our Semaglutide Protocol Guide or explore our research-grade semaglutide.

GLP-1 Receptor Biology and Semaglutide’s Molecular Design

The GLP-1 System: A Brief Overview

Glucagon-like peptide-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient ingestion. Native GLP-1 activates the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed across multiple organ systems including pancreatic beta cells, the gastrointestinal tract, the central nervous system (hypothalamus, brainstem, hippocampus), the cardiovascular system, and the kidneys.

Upon binding, the GLP-1R activates adenylyl cyclase via Gαs coupling, increasing intracellular cyclic AMP (cAMP) and triggering downstream signaling cascades including protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). These pathways mediate glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and central appetite regulation through hypothalamic and brainstem circuits (Müller et al., 2019).

However, native GLP-1 has a plasma half-life of only approximately 2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance, making it therapeutically impractical in its unmodified form.

Semaglutide’s Engineered Protraction: Why the Extended Half-Life

Semaglutide was developed through systematic molecular engineering to achieve once-weekly dosing — a substantial advancement over earlier GLP-1 receptor agonists. The molecule shares 94% structural homology with native human GLP-1 but incorporates three critical modifications:

1. Amino acid substitution at position 8 — Alanine is replaced with α-aminoisobutyric acid (Aib), conferring resistance to DPP-4 enzymatic degradation.

2. Amino acid substitution at position 34 — Lysine is replaced with arginine, preventing fatty acid attachment at an undesired position.

3. C-18 fatty diacid chain at position 26 — A spacer links a C-18 fatty diacid to lysine at position 26, enabling high-affinity, reversible binding to serum albumin.

This albumin-binding mechanism is the primary driver of semaglutide’s extended half-life of approximately 165 hours (~7 days), allowing once-weekly administration. The fatty acid chain promotes strong, non-covalent albumin association in plasma, creating a circulating depot that reduces renal clearance and protects against enzymatic degradation (Lau et al., 2015). Research has demonstrated that the specific combination of the C-18 fatty diacid with the optimized linker chemistry distinguishes semaglutide from earlier GLP-1RAs like liraglutide, which uses a shorter C-16 fatty acid and achieves only a ~13-hour half-life (Knudsen & Lau, 2019).

Semaglutide Mechanism of Action: Multi-Organ Effects

Research has shown that semaglutide’s mechanism of action extends well beyond simple incretin-mediated insulin secretion. Key mechanistic pathways identified in published studies include:

• Central appetite regulation — Semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in the arcuate nucleus, paraventricular nucleus, and area postrema, reducing hunger signaling and caloric intake.

• Gastric motility — Delayed gastric emptying contributes to postprandial satiety, though this effect may attenuate with chronic exposure.

• Anti-inflammatory pathways — Research has identified reductions in C-reactive protein (CRP), interleukin-6, and TNF-α, potentially mediating cardiovascular and metabolic benefits independent of weight loss.

• Hepatic lipid metabolism — GLP-1R activation in hepatocytes reduces de novo lipogenesis, enhances fatty acid oxidation, and improves hepatic insulin sensitivity.

• Cardiovascular effects — Direct vascular effects including improved endothelial function, reduced oxidative stress, and attenuation of atherosclerotic plaque inflammation have been documented in preclinical models.

The STEP Clinical Trial Program: Semaglutide Weight Management Research

The Semaglutide Treatment Effect in People with obesity (STEP) program represents the largest clinical trial program ever conducted for a weight management intervention, enrolling over 10,000 participants across multiple randomized, double-blind, placebo-controlled trials.

STEP Trial Results Summary

STEP 1: The Landmark Weight Loss Study

The STEP 1 trial enrolled 1,961 adults with BMI ≥30 (or ≥27 with weight-related comorbidities) without diabetes and randomized them 2:1 to receive once-weekly subcutaneous semaglutide 2.4 mg or placebo, plus lifestyle intervention. At 68 weeks, researchers observed a mean body weight change of −14.9% in the semaglutide group compared with −2.4% in the placebo group (estimated treatment difference: −12.4 percentage points; P<0.001). Notably, 86.4% of semaglutide-treated participants achieved ≥5% weight loss, 69.1% achieved ≥10%, and 50.5% achieved ≥15% (Wilding et al., 2021).

STEP 2: Participants With Type 2 Diabetes

The STEP 2 trial specifically studied participants with overweight/obesity and type 2 diabetes (n=1,210). While the weight loss was attenuated compared to the non-diabetic population — a consistent finding across GLP-1RA research — semaglutide 2.4 mg still achieved a mean weight reduction of −9.6% versus −3.4% with placebo, along with substantial improvements in HbA1c (Davies et al., 2021).

STEP 5: Two-Year Durability Data

Critically for the research community, the STEP 5 trial demonstrated that weight loss with semaglutide 2.4 mg is sustained over 104 weeks. The mean body weight change from baseline to week 104 was −15.2% in the semaglutide group versus −2.6% with placebo (ETD: −12.6 percentage points; P<0.0001). This 2-year data established that semaglutide-mediated weight reduction is durable when administration is continued, exceeding weight loss reported at similar time points for other pharmacological interventions (Garvey et al., 2022).

SELECT Cardiovascular Outcomes Trial: Beyond Metabolic Parameters

Study Design and Results

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a pivotal cardiovascular outcomes trial that fundamentally expanded the evidence base for semaglutide research. This multicenter, double-blind, randomized, placebo-controlled trial enrolled 17,604 patients aged ≥45 years with preexisting cardiovascular disease and BMI ≥27 but without diabetes.

Participants were randomized 1:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo. The primary endpoint was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE).

At a mean follow-up of 39.8 months, a primary cardiovascular endpoint event occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, representing a 20% relative risk reduction (HR 0.80; 95% CI 0.72–0.90; P<0.001) (Lincoff et al., 2023).

Significance for Research

The SELECT trial was the first to demonstrate cardiovascular risk reduction with any pharmacological weight management agent in a non-diabetic population with established CVD. This finding has profound implications for understanding the relationship between GLP-1R activation, metabolic improvement, and cardiovascular outcomes — raising important questions about whether the benefits stem primarily from weight loss, direct vascular effects of GLP-1R activation, anti-inflammatory mechanisms, or a combination of these pathways.

Prespecified analyses showed that semaglutide improved outcomes across subgroups including those with heart failure at baseline, various levels of baseline BMI, and across demographic groups (Deanfield et al., 2024).

FLOW Kidney Outcomes Trial: Renal Protection

Study Design and Key Findings

The FLOW trial investigated whether semaglutide could reduce the progression of chronic kidney disease (CKD) in patients with type 2 diabetes. A total of 3,533 participants with T2D and CKD (eGFR 25–75 mL/min/1.73 m² with albuminuria) were randomized to subcutaneous semaglutide 1.0 mg weekly or placebo.

The primary composite outcome — major kidney disease events (kidney failure, ≥50% eGFR reduction, or death from kidney-related or cardiovascular causes) — occurred in significantly fewer semaglutide-treated participants: 24% relative risk reduction (HR 0.76; 95% CI 0.66–0.88; P=0.0003). The mean annual eGFR slope was less steep by 1.16 mL/min/1.73 m² in the semaglutide group (P<0.001), indicating slowed kidney function decline. The risk of death from any cause was 20% lower with semaglutide (HR 0.80; P=0.01) (Perkovic et al., 2024).

The trial was stopped early at a prespecified interim analysis due to overwhelming efficacy — a rare event in nephrology clinical trials that underscores the magnitude of the observed benefit.

Mechanistic Implications

Research suggests that semaglutide’s renal effects may involve multiple pathways: reduction in intraglomerular pressure via tubuloglomerular feedback modulation, attenuation of renal inflammation, improvements in glycemic control and blood pressure, and weight loss-mediated reductions in hyperfiltration. The relative contribution of each pathway remains an active area of investigation.

Emerging Research Beyond Metabolic Disease

Neuroprotection and Neurodegenerative Disease

One of the most intriguing frontiers in semaglutide research involves its potential neuroprotective effects. GLP-1 receptors are widely expressed in the central nervous system, and preclinical studies have documented that GLP-1RAs can reduce neuroinflammation, promote neuronal survival, enhance synaptic plasticity, and reduce amyloid-beta accumulation.

A large pharmacoepidemiological study by Wang et al. (2024) found that semaglutide use was associated with a 40–70% reduced risk of first-time Alzheimer’s disease diagnosis in patients with type 2 diabetes compared with other antidiabetic medications. While observational, this finding has prompted Novo Nordisk to initiate the EVOKE and EVOKE+ phase 3 trials evaluating oral semaglutide in early Alzheimer’s disease.

Preclinical research has also shown that semaglutide administration reduced tau phosphorylation, attenuated microglial activation, and improved cognitive performance in transgenic Alzheimer’s disease mouse models. These findings suggest GLP-1R-mediated neuroprotective pathways that may be independent of metabolic effects (Hölscher, 2022).

NASH/MAFLD (Metabolic-Associated Steatotic Liver Disease)

Semaglutide has demonstrated significant efficacy in research on nonalcoholic steatohepatitis (NASH), now increasingly referred to as metabolic dysfunction-associated steatohepatitis (MASH). In a phase 2 randomized controlled trial, Newsome et al. (2021) found that once-daily subcutaneous semaglutide at 0.4 mg resulted in NASH resolution without worsening of fibrosis in 59% of treated participants compared to 17% with placebo (P<0.001). The mean weight loss in the 0.4 mg group was 13% versus 1% with placebo.

A subsequent phase 3 trial published in 2024 demonstrated that once-weekly semaglutide 2.4 mg improved liver histologic results in patients with MASH and moderate or advanced liver fibrosis, further supporting the therapeutic potential of GLP-1R activation in hepatic research contexts.

Addiction Research: Alcohol and Substance Use

Perhaps the most unexpected line of semaglutide research involves its effects on addictive behaviors. GLP-1 receptors are expressed in mesolimbic reward circuits, including the ventral tegmental area and nucleus accumbens, suggesting a biological basis for modulating reward-seeking behavior.

A phase 2, double-blind randomized trial by Klausen et al. (2025) evaluated low-dose semaglutide (escalating from 0.25 to 1.0 mg/week) in 48 adults with alcohol use disorder. Researchers observed that semaglutide significantly reduced laboratory alcohol self-administration (β = −0.48; P=0.01), drinks per drinking day (β = −0.41; P=0.04), and weekly alcohol craving (β = −0.39; P=0.01) compared to placebo. A treatment-by-time interaction also indicated reduced cigarette consumption in a subsample with current tobacco use.

Separately, a large pharmacoepidemiological study published in Nature Communications found that semaglutide was associated with a 50–56% lower risk for both the incidence and recurrence of alcohol use disorder compared with other anti-obesity medications (Wang et al., 2024).

These findings have prompted multiple large-scale randomized clinical trials evaluating GLP-1RAs for substance use disorders, representing a potentially transformative application of GLP-1 receptor biology in behavioral neuroscience research.

Comparison With Other GLP-1 Receptor Agonists

GLP-1 Receptor Agonist Comparison Table

Tirzepatide is a dual GIP/GLP-1 receptor agonist, not a pure GLP-1RA, and is included for comparative context. For a detailed comparison, see our Semaglutide vs. Tirzepatide Comparison.

Semaglutide vs. Liraglutide

The STEP 8 trial directly compared once-weekly subcutaneous semaglutide 2.4 mg with once-daily liraglutide 3.0 mg in adults with overweight or obesity without diabetes. Researchers found that semaglutide produced significantly greater weight loss (−15.8% vs. −6.4%; ETD: −9.4 percentage points; P<0.001) (Rubino et al., 2022). The greater efficacy of semaglutide is attributed to its enhanced albumin binding, reduced DPP-4 susceptibility, and more sustained receptor engagement due to higher and more consistent plasma levels from once-weekly dosing.

Semaglutide vs. Dulaglutide

While no head-to-head weight management trial exists, the SUSTAIN trial program for semaglutide in diabetes consistently showed greater HbA1c reduction and weight loss compared to dulaglutide in the AWARD program. A meta-analysis by comparative real-world studies confirmed semaglutide’s superior efficacy in both glycemic control (HbA1c reduction) and weight loss endpoints compared to dulaglutide, likely attributable to the structural differences in protraction mechanisms — semaglutide’s fatty acid acylation versus dulaglutide’s Fc fusion approach.

Pharmacokinetics: Oral vs. Subcutaneous Semaglutide

Subcutaneous Semaglutide

Subcutaneous semaglutide demonstrates predictable, dose-proportional pharmacokinetics with steady-state plasma concentrations achieved after 4–5 weekly doses. Peak plasma concentrations (Cmax) occur at approximately 1–3 days post-injection. The absolute bioavailability of subcutaneous semaglutide approaches ~89%, and the compound is primarily eliminated through proteolytic degradation with minimal renal excretion of intact peptide (Overgaard et al., 2021).

Oral Semaglutide: The SNAC Innovation

The development of oral semaglutide represents a breakthrough in peptide delivery science. Oral semaglutide is co-formulated with sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC), an absorption enhancer that transiently increases local gastric pH and promotes transcellular absorption of intact semaglutide across the gastric epithelium.

Research has shown that SNAC creates a localized microenvironment around the tablet that buffers gastric acid and promotes peptide solubility and permeability. The oral bioavailability is approximately 0.4–1%, which, while low in absolute terms, is sufficient to achieve therapeutically relevant plasma concentrations at higher nominal doses (3, 7, or 14 mg daily) (Aroda et al., 2022; Granhall et al., 2019).

Critical dosing conditions identified in pharmacokinetic studies include administration in the fasting state with no more than 120 mL of water, followed by a 30-minute post-dose fasting period, as food and fluid significantly reduce oral semaglutide absorption (Bækdal et al., 2021).

Dose-Response Relationships in Research Settings

In published clinical research, semaglutide has been studied across a wide range of doses, revealing clear dose-response relationships:

• Glycemic control (T2D): In the SUSTAIN trials, researchers administered subcutaneous semaglutide at doses of 0.5 mg and 1.0 mg weekly, observing dose-dependent HbA1c reductions of approximately 1.2–1.8%.

• Weight management: The 2.4 mg weekly dose was selected for the STEP program based on dose-finding studies showing greater weight loss with escalation beyond the 1.0 mg diabetes dose.

• NASH research: In the phase 2 NASH trial, daily subcutaneous doses of 0.1, 0.2, and 0.4 mg were investigated. The 0.4 mg dose produced the highest rate of NASH resolution (59%) and the greatest weight loss (13%).

• Kidney protection: The FLOW trial used the 1.0 mg weekly subcutaneous dose — the standard diabetes dose — rather than the 2.4 mg weight management dose.

These varied dosing protocols across different research contexts illustrate the importance of dose optimization for specific research endpoints.

Safety Profile From Clinical Data

Gastrointestinal Events

Across the STEP program and SELECT trial, gastrointestinal adverse events were the most frequently reported side effects. In STEP 1, nausea and diarrhea were the most common adverse events with semaglutide; they were typically transient, mild-to-moderate in severity, and subsided with continued administration. Discontinuation due to gastrointestinal events occurred in 4.5% of semaglutide-treated participants versus 0.8% with placebo (Wilding et al., 2021).

Cardiovascular Safety

The SELECT trial provided the most comprehensive cardiovascular safety and efficacy data, with a mean treatment exposure of 34.2 months. Beyond the primary MACE reduction, no new cardiovascular safety signals were identified. Adverse events leading to permanent discontinuation were higher in the semaglutide group (16.6% vs. 8.2%), primarily driven by gastrointestinal intolerance (Lincoff et al., 2023).

Pancreatitis and Thyroid Concerns

Research has documented small increases in serum lipase and amylase levels with semaglutide, though rates of confirmed pancreatitis have been very low across all major trials. Regarding thyroid C-cell tumors — observed in rodent models at supraphysiological exposures — no causal signal has been identified in clinical trials, though semaglutide carries a boxed warning based on the preclinical finding. Long-term pharmacovigilance data continue to accumulate.

Gallbladder Events

An increased incidence of cholelithiasis (gallstones) has been observed with semaglutide, consistent with the known association between rapid weight loss and gallstone formation. This is considered a class effect of potent weight loss interventions rather than a specific pharmacological concern.

Future Research Directions

The semaglutide research pipeline continues to expand into novel therapeutic areas:

• Alzheimer’s disease: The EVOKE and EVOKE+ phase 3 trials are evaluating oral semaglutide 14 mg in early-stage Alzheimer’s disease, with primary endpoints including cognitive function measures.

• Heart failure with preserved ejection fraction (HFpEF): The STEP-HFpEF trials have shown significant improvements in heart failure symptoms, physical limitations, and body weight in patients with obesity-related HFpEF.

• Addiction medicine: Multiple randomized trials are underway evaluating semaglutide and other GLP-1RAs for alcohol use disorder and opioid use disorder.

• Higher-dose formulations: Novo Nordisk is investigating a 7.2 mg once-weekly subcutaneous dose, with early data showing enhanced weight loss (~20%) compared to the 2.4 mg dose.

• Peripheral artery disease, obstructive sleep apnea, and polycystic ovary syndrome are all active areas of semaglutide research.

For researchers interested in GLP-1 receptor agonist compounds, explore IronPeak’s research-grade semaglutide or visit our Semaglutide Protocol Guide for formulation and handling information. See also our Semaglutide vs. Tirzepatide Comparison for a detailed analysis of dual vs. single receptor agonist approaches.

Frequently Asked Questions

What is semaglutide and how does it work as a GLP-1 receptor agonist?

Semaglutide is a synthetic GLP-1 receptor agonist with 94% structural homology to native human GLP-1. Research has demonstrated that it works by activating GLP-1 receptors across multiple organ systems, enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system signaling. Its engineered C-18 fatty diacid side chain enables strong albumin binding, providing a half-life of approximately 7 days for once-weekly dosing.

What were the main findings of the STEP clinical trial program?

The STEP trials demonstrated that once-weekly subcutaneous semaglutide 2.4 mg produces mean weight loss of approximately 14.9–16.0% over 68 weeks in adults with overweight or obesity without diabetes. STEP 5 confirmed this weight loss is sustained at −15.2% over 104 weeks. Across all STEP trials, the majority of participants achieved clinically meaningful weight reduction thresholds of ≥5%, ≥10%, and ≥15%.

What did the SELECT cardiovascular outcomes trial show about semaglutide?

The SELECT trial (n=17,604) demonstrated that semaglutide 2.4 mg weekly reduced the risk of major adverse cardiovascular events (death from cardiovascular causes, nonfatal MI, or nonfatal stroke) by 20% compared with placebo in patients with established cardiovascular disease and overweight/obesity but without diabetes (HR 0.80; P<0.001) over a mean follow-up of 39.8 months.

How does semaglutide compare to liraglutide for weight loss in research?

In the head-to-head STEP 8 trial, once-weekly semaglutide 2.4 mg produced significantly greater weight loss than once-daily liraglutide 3.0 mg (−15.8% vs. −6.4%; P<0.001). Semaglutide’s superior efficacy is attributed to its enhanced molecular design enabling greater DPP-4 resistance, stronger albumin binding, and more consistent plasma levels from weekly dosing.

What kidney outcomes has semaglutide research demonstrated?

The FLOW trial showed that semaglutide 1.0 mg weekly reduced major kidney disease events (kidney failure, ≥50% eGFR reduction, or renal/cardiovascular death) by 24% (HR 0.76; P=0.0003) in patients with T2D and CKD. The trial was stopped early due to overwhelming efficacy — with reductions in kidney-specific events, cardiovascular death, and all-cause mortality.

Is there semaglutide research in neurodegenerative disease?

Preclinical research has demonstrated neuroprotective effects of semaglutide including reduced neuroinflammation, decreased amyloid-beta accumulation, and improved cognitive function in animal models. Large observational studies have found 40–70% reduced Alzheimer’s disease risk associated with semaglutide use. Phase 3 clinical trials (EVOKE/EVOKE+) are currently evaluating oral semaglutide in early Alzheimer’s disease.

What is the difference between oral and subcutaneous semaglutide?

Subcutaneous semaglutide has approximately 89% bioavailability and is dosed weekly (0.5–2.4 mg depending on indication). Oral semaglutide is co-formulated with the absorption enhancer SNAC and has approximately 0.4–1% oral bioavailability, requiring higher nominal doses (up to 14 mg daily). Both formulations produce the same semaglutide molecule in circulation; the oral version requires fasting administration conditions.

What are the most common side effects observed in semaglutide clinical trials?

Across the STEP and SELECT trial programs, gastrointestinal events — primarily nausea, diarrhea, vomiting, and constipation — were the most commonly reported adverse events. These were typically transient, mild-to-moderate in severity, and most prevalent during dose escalation. Discontinuation due to gastrointestinal events occurred in approximately 4–7% of semaglutide-treated participants across major trials.

Conclusion

Semaglutide research has produced one of the most robust evidence bases in modern peptide pharmacology. From the molecular elegance of its engineered albumin-binding protraction mechanism to the striking clinical outcomes across the STEP, SELECT, and FLOW programs, semaglutide exemplifies how rational peptide design can yield compounds with multi-system therapeutic potential.

The expansion of semaglutide research into neuroprotection, liver disease, addiction medicine, and heart failure signals a broader paradigm shift in understanding GLP-1 receptor biology — one where incretin signaling intersects with inflammation, neurodegeneration, reward circuitry, and organ protection in ways that are only beginning to be fully characterized.

For researchers seeking high-quality GLP-1 receptor agonist compounds, Iron Peak Peptides offers research-grade semaglutide with third-party purity verification. Explore our Semaglutide Protocol Guide for research application guidance, and browse our Peptide Glossary for terminology definitions.

Research References

1. Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” The New England Journal of Medicine, 384(11), 989-1002, 2021. DOI: 10.1056/NEJMoa2032183

2. Davies M, Færch L, Jeppesen OK, et al. “Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.” The Lancet, 397(10278), 971-984, 2021. DOI: 10.1016/S0140-6736(21)00213-0

3. Wadden TA, Bailey TS, Billings LK, et al. “Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.” JAMA, 325(14), 1403-1413, 2021. DOI: 10.1001/jama.2021.1831

4. Rubino D, Abrahamsson N, Davies M, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA, 325(14), 1414-1425, 2021. DOI: 10.1001/jama.2021.3224

5. Garvey WT, Batterham RL, Bhatta M, et al. “Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.” Nature Medicine, 28(10), 2083-2091, 2022. DOI: 10.1038/s41591-022-02026-4

6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” The New England Journal of Medicine, 389(24), 2221-2232, 2023. DOI: 10.1056/NEJMoa2307563

7. Perkovic V, Tuttle KR, Rossing P, et al. “Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.” The New England Journal of Medicine, 391(2), 109-121, 2024. DOI: 10.1056/NEJMoa2403347

8. Newsome PN, Buchholtz K, Cusi K, et al. “A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.” The New England Journal of Medicine, 384(12), 1113-1124, 2021. DOI: 10.1056/NEJMoa2028395

9. Rubino DM, Greenway FL, Khalid U, et al. “Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.” JAMA, 327(2), 138-150, 2022. DOI: 10.1001/jama.2021.23619

10. Klausen MK, Thomsen M, Wortwein G, et al. “Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial.” JAMA Psychiatry, 82(4), 369-379, 2025. DOI: 10.1001/jamapsychiatry.2024.4789

11. Wang W, Wang Q, Bhau BS, et al. “Associations of semaglutide with incidence and recurrence of alcohol use disorder.” Nature Communications, 15, 4548, 2024. DOI: 10.1038/s41467-024-48780-6

12. Wang W, Bhau BS, et al. “Associations of semaglutide with first-time diagnosis of Alzheimer disease.” Alzheimer’s & Dementia, 2024. DOI: 10.1002/alz.14313

13. Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Frontiers in Endocrinology, 10, 155, 2019. DOI: 10.3389/fendo.2019.00155

14. Overgaard RV, Navarria A, Hertz CL, Ingwersen SH. “Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.” Clinical Pharmacokinetics, 60(10), 1335-1348, 2021. DOI: 10.1007/s40262-021-01025-x

15. Aroda VR, Blonde L, Engel SS. “A new era for oral peptides: SNAC and the development of oral semaglutide for type 2 diabetes.” Reviews in Endocrine and Metabolic Disorders, 23(5), 979-994, 2022. DOI: 10.1007/s11154-022-09735-8

16. Deanfield J, Verma S, Scirica BM, et al. “Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.” The Lancet, 404(10454), 773-786, 2024. DOI: 10.1016/S0140-6736(24)01498-3

17. Müller TD, Finan B, Bloom SR, et al. “Glucagon-like peptide 1 (GLP-1).” Molecular Metabolism, 30, 72-130, 2019. DOI: 10.1016/j.molmet.2019.09.010

Research Disclaimer: This article is provided for educational and informational purposes only and is intended for researchers and scientific professionals. The content herein reviews published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. All peptides referenced are intended for research purposes only and are not for human consumption outside of IRB-approved clinical research. Always consult qualified medical professionals regarding health decisions. Iron Peak Peptides does not claim that any product is intended to diagnose, treat, cure, or prevent any disease.

Related Research

• → Semaglutide 10mg

• → Where to Buy Semaglutide for Research (2026 Guide)

• → Semaglutide – Research Compound Profile

• → Semaglutide Side Effects in Research: What Studies Reveal

• → Will Semaglutide Be Banned for Research in 2026? Full Update